A major development in the psychedelic space is the introduction of fast-track review processes.
The U.S. Food and Drug Administration is exploring ways to accelerate the approval of promising treatments, including ibogaine.
Fast-tracking allows certain treatments to move through the approval process more quickly.
This is typically reserved for therapies that address serious or unmet medical needs.
Ibogaine is being considered due to its potential to treat:
If ibogaine meets the criteria, it could enter clinical trials more rapidly and move closer to approval.
Until approval is granted, treatment remains accessible mainly in countries like Mexico.
We connect you with trusted ibogaine treatment providers.
👉 All contact and inquiries go through Iboga World:
https://ibogaworld.com/contact